Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
| Autor: | Marianne Graflund, Bengt Sorbe, Margareta Lood, Karin Boman, Marie Swahn, Henric Malmström, Rene Bangshoj, György Horvath |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Phases of clinical research Docetaxel Kaplan-Meier Estimate Carcinoma Ovarian Epithelial Disease-Free Survival Drug Administration Schedule Carboplatin chemistry.chemical_compound Ovarian carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Stage iib Neoplasms Glandular and Epithelial Prospective Studies Aged Neoplasm Staging Aged 80 and over Ovarian Neoplasms business.industry Obstetrics and Gynecology Middle Aged medicine.disease Survival Rate Treatment Outcome chemistry Toxicity Female Taxoids First line chemotherapy business Ovarian cancer medicine.drug |
| Zdroj: | International Journal of Gynecologic Cancer. 22:47-53 |
| ISSN: | 1525-1438 1048-891X |
| DOI: | 10.1097/igc.0b013e318234fa3a |
| Popis: | ObjectivesThe purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a series of patients with advanced-stage ovarian carcinoma treated with a first-line weekly docetaxel and 3 weekly carboplatin regimen.MethodsAll eligible patients were treated with intravenous docetaxel (30 mg/m2) on days 1, 8, and 15, and carboplatin (area under the curve, 5) on day 1; every 21 days for at least 6 cycles.ResultsOne hundred six patients received at least one cycle of primary chemotherapy (median, 6.0; range, 1–9), and they were evaluable for toxicity assessment. Eighty-five patients had evaluable (measurable) disease and received at least 3 courses of chemotherapy and were evaluable for clinical response rate. The overall response rate was 78.8% (95% confidence interval, 70.1%–87.5%), and the biochemical response 92.8% (95% confidence interval, 87.2%–98.4%). The median progression-free survival was 12.0 months and the median overall survival was 35.3 months. Thirty-six patients (34.0%) experienced grades 3 and 4 neutropenia, which resulted in the removal of 3 patients. Six patients (5.7%) experienced grades 3 or 4 thrombocytopenia. No patients experienced grade 3 to grade 4 sensory neuropathy. Epiphora, nail changes, and fatigue were frequently recorded nonhematologic adverse effects.ConclusionsThe tolerable hematologic toxicity (no need for colony-stimulating factors) and the low rate of neurotoxicity (only grades 1–2) and response rates in line with the standard 3-week paclitaxel-carboplatin regimen for advanced primary ovarian carcinoma after suboptimal cytoreductive surgery make this regimen an interesting alternative in selected patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|